Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Adenocarcinoma of Lung 5NSCLC 4Meningeal Carcinomatosis 4Brain Neoplasms 4Lung Neoplasms 3Pleural Effusion, Malignant 1Non Small Cell Lung Cancer NSCLC 1Neoplasm, Residual 1Multiple Primary Lung Cancers 1EGF-R Positive Non-Small Cell Lung Cancer 1Carcinoma 1Adenocarcinoma 1

Interventions

durvalumab 1ceralasertib 1aflutinib 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non Small Cell Lung Cancer NSCLC × aflutinib × Clear all
NCT07087223 2025-07-25

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Peking University Cancer Hospital & Institute

Phase 1/2 Recruiting
42 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡